Skip to main content
Home

Main navigation

  • Home
  • News
  • About HIV
  • About us
Search
Donate
Donate now

With Gift Aid, your generous donation of £10 would be worth £12.50 at no extra cost to you.

I am a UK taxpayer and I understand that if I pay less Income and /or Capital Gains Tax than the amount of Gift Aid claimed on all my donations in the relevant tax year, it is my responsibility to pay any difference.

In our 35th year we’re asking people to donate £35 – that’s just £1 for every year we’ve been providing life-changing information. Any donation you make helps us continue our work towards a world where HIV is no longer a threat to health or happiness.

  • £5 allows us to reach millions of people globally with accurate and reliable resources about HIV prevention and treatment.
  • £10 helps us produce news and bulletins on the latest developments in HIV for healthcare staff around the world.
  • £35 means we can empower more people living with HIV to challenge stigma with our information workshops, videos and broadcasts.

Showing 7 news articles about Antibody-based treatment

Filters Content type: Editors' picks Topic: Antibody-based treatment
Pharmaceutical industry

Long-suffering CytoDyn withdraws HIV approval application for leronlimab, blaming clinical research organization

Editor's pick
FierceBiotech
1 November 2022
Antibody-based treatment

GSK's ViiV gives early look at HIV broadly neutralizing antibody's power, eyes long-acting combo trial

Editor's pick
FierceBiotech
28 October 2022
Antibody-based treatment

ViiV Healthcare presents positive proof-of-concept findings for N6LS, an investigational, broadly neutralising antibody (bNAb) offering a potential new approach for the treatment of HIV

Editor's pick
ViiV press release
26 October 2022
The search for a cure

Combination Anti-HIV Antibody Infusions Suppress Virus for Sustained Period

Editor's pick
HIV.gov
6 June 2022
The search for a cure

Antibody therapy controls HIV for months in new clinical trial

Editor's pick
The Rockerfeller University
22 April 2022
Antibody-based treatment

New approach for delivery of anti-HIV antibody therapy shows promise in phase I clinical trial

Editor's pick
EurekAlert
13 April 2022
Antibody-based prevention

Why broadly neutralising antibodies might be the next big thing in HIV

Editor's pick
Spotlight
8 February 2021

Refine search

By content type
From
To
Topic

About us

NAM is a charity based in the United Kingdom. We work to change lives by sharing information about HIV & AIDS. We believe independent, clear and accurate information is vital in the fight against HIV & AIDS.

Our information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.

Read more about us

Connect with us

  • Twitter
  • Facebook
  • YouTube
  • Instagram
Subscribe to emails & newsfeeds

Login to our clinic portal
Donate

Visit NAM’s other websites: clinic.nam.org.uk | infohep.org | prepineurope.org | about-hiv.info | pro-vich.info | hiv-lens.org

© NAM Publications 2023, all rights reserved. NAM is not responsible for the content of external websites.

Company limited by guarantee. Registered in England & Wales, number: 2707596. Registered charity, number: 1011220

Footer menu

Show — Footer menu Hide — Footer menu
  • Contact
  • Jobs
  • Terms of Use
  • Accessibility
  • Privacy Policy
  • Cookies
  • Manage cookies